安必平收盘上涨3.54%，滚动市盈率1198.50倍，总市值26.82亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - Anbiping's closing stock price on June 27 was 28.66 yuan, reflecting a 3.54% increase, with a rolling PE ratio of 1198.50 times and a total market capitalization of 2.682 billion yuan [1] - The average PE ratio for the medical device industry is 49.70 times, with a median of 35.80 times, positioning Anbiping at the 122nd rank within the industry [1][2] Group 2 - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business of Anbiping includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, Anbiping reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1]